These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 6096471)

  • 1. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
    Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A
    J Med; 1984; 15(2):149-60. PubMed ID: 6096471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of laser-nephelometry in evaluating fibrinogenaemia in patients with hepatocarcinoma and cirrhosis.
    Girolami A; Antico S; Pengo V; Ruffato G; Callegari F; Cappellato M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):920-7. PubMed ID: 2419222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.
    Gralnick HR; Givelber H; Abrams E
    N Engl J Med; 1978 Aug; 299(5):221-6. PubMed ID: 207986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time.
    Van Cott EM; Smith EY; Galanakis DK
    Am J Clin Pathol; 2002 Aug; 118(2):263-8. PubMed ID: 12162688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfibrinogenemia and prolonged clotting times in a Turner syndrome patient with hepatocellular carcinoma.
    Zhao X; Wang Z; Cao L; Zhang W; Bai X; Dong N; Yu Z; Ruan C
    Blood Coagul Fibrinolysis; 2010 Jul; 21(5):398-405. PubMed ID: 20410814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acquired dysfibrinogenemia in a child in the course of a liver disease].
    Maak B; Meyer M; Dietze H
    Monatsschr Kinderheilkd; 1990 Aug; 138(8):446-50. PubMed ID: 2215508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.
    von Felten A; Straub PW; Frick PG
    N Engl J Med; 1969 Feb; 280(8):405-9. PubMed ID: 4303132
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma.
    Doğan UB; Cindoruk M; Dumlu S; Unlü R; Unal S
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):476-7. PubMed ID: 9494860
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet aggregation in portal cirrhosis.
    Ballard HS; Marcus AJ
    Arch Intern Med; 1976 Mar; 136(3):316-9. PubMed ID: 4041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin clotting time and fibrin polymerization in liver cirrhosis.
    Szczepański M; Habior A; Szczepanik A; Soszka A; Grel K
    Mater Med Pol; 1994; 26(3):87-90. PubMed ID: 7603083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfibrinogenaemia and primary hepato-cellular carcinoma.
    Barr RD; Ouna N; Simpson JG; Bagshawe AF
    Q J Med; 1976 Oct; 45(180):647-59. PubMed ID: 188064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum selenium concentration in patients with liver cirrhosis and hepatocellular carcinoma.
    Buljevac M; Romić Z; Vucelić B; Banić M; Krznarić Z; Plesko S
    Acta Med Croatica; 1996; 50(1):11-4. PubMed ID: 8776109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reliability of tests for fibrinogen (fibrin) degradation products in plasma with thrombin coagulase, reptilase and thrombin clotting time (author's transl)].
    Wenzel E; Holzhüter H; Muschietti F; Angelkort B; Ochs HG; Pusztai-Markos S; Nowak H; Stürner H
    Dtsch Med Wochenschr; 1974 Apr; 99(15):746-56. PubMed ID: 4858105
    [No Abstract]   [Full Text] [Related]  

  • 14. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?
    Ben-Ari Z; Osman E; Hutton RA; Burroughs AK
    Am J Gastroenterol; 1999 Oct; 94(10):2977-82. PubMed ID: 10520855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Unexpectedly prolonged thrombin time].
    Barth A; Furlan M; Lämmle B
    Schweiz Med Wochenschr; 1993 Mar; 123(12):523-9. PubMed ID: 8475358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinopeptide A in liver cirrhosis: evidence against a major contribution of disseminated intravascular coagulation to coagulopathy of chronic liver disease.
    Mombelli G; Fiori G; Monotti R; Haeberli A; Straub PW
    J Lab Clin Med; 1993 Jan; 121(1):83-90. PubMed ID: 8426084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of coagulation screening test results in two cases having dysfibrinogen].
    Terasawa F; Sasaki Y; Ishikawa S; Nakagoshi R; Furihata K; Katsuyama T; Okumura N
    Rinsho Byori; 1996 Aug; 44(8):791-6. PubMed ID: 8816067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma amino acid levels in patients with colorectal cancers and liver cirrhosis with hepatocellular carcinoma.
    Lee JC; Chen MJ; Chang CH; Tiai YF; Lin PW; Lai HS; Wang ST
    Hepatogastroenterology; 2003; 50(53):1269-73. PubMed ID: 14571716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
    Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
    Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.